Hemodynamics is an area of neonatology that is marked more by what we do not know than what we do. What is clear is that it is much more complex than just measuring blood pressure (BP). Early postnatal preterm hemodynamic pathophysiology is characterized by low systemic blood flow (SBF), possibly relating to a mix of afterload compromise, left-to-right shunting through the unconstricted ductus and to the circulatory effects of ventilation. After B24 h of age, vasodilatation seems to be the dominant pathology. In the face of this complexity, a one-size-fits-all approach to treatment that will be applicable in a large clinical trial may prove elusive. The possibility of using a measure of both BP and SBF to target an appropriate treatment needs to be explored.
Introduction
The title of this conference series is an intriguing one, in that the term 'versus' suggests that there can be a conflict between evidence and experience; although in an ideal world, what the evidence tells us and what we observe in our clinical experience should be identical, and often it is. In the real world, there can be conflict, with therapies that many neonatologists believe from experience will benefit their patients, while randomized trials fail to show benefit (think continuous positive airway pressure). Also mechanistic derivations obtained from randomized controlled trial results can bear no relationship to real-life observations. Why is this? Traditionally, this difference is dismissed as bias on the part of the clinician, and again this will often be true, but may be there is more to it than this, and may be there are lessons to be learned from the reasons for the differences between evidence and experience.
In our work on neonatal hemodynamics, what is constantly striking is how different the hemodynamics are, both between individual babies and in the same baby at different times. This heterogeneity contrasts strikingly with often rather simplistic generalizations about mechanisms, which we apply in designing clinical trials. While not wanting to undermine the importance of high-level evidence, I fear there is a danger that we might overlook the potential for experience (or close observation) from individual patients to stimulate new ideas. I can trace the origins of most of my research ideas, not from looking at odds ratio charts, but from observations made on single cases that told me that accepted truths could not possibly be true.
Hence in this paper, I will take you from the lessons of experiential anecdote, through our observational studies, to our attempts to develop an evidence base for this field of preterm hemodynamics. This will not be a systematic review but the conclusion, similar to most systematic reviews, will be frustratingly inconclusive, and I will end this paper with the inevitable directive that more research is needed. However, if I can make you question the established truths in this field, I will have achieved my goal.
The field of preterm circulatory support is unusual, in that what has been accepted for many years as 'the truth' would pass none of the current tests for a high-level evidence base. Yet these truths are still fervently believed by many. Using the interactive feedback system at the Evidence vs Experience Conference at the start of this talk, the majority of the audience thought that blood pressure (BP) was the best measure of systemic blood flow (SBF), and that there was evidence that circulatory support improves neurodevelopmental outcomes. Read ony.
Traditional truths in preterm circulatory support These established truths in preterm circulatory support have been handed down from two observations. First, there were studies that associated head ultrasound evidence of brain injury with lower BP.
1,2 It should be emphasized that this was predominantly head ultrasound evidence; there is less evidence relating low BP to adverse neurodevelopmental outcomes, although some data are available. 3 The second truth is related to the concept of impaired autoregulation of the preterm cerebral circulation. This hypothesis suggests that the autoregulatory plateau was limited in preterm babies. As the autoregulatory plateau is the range of BP over which cerebral blood flow is kept constant, at BPs below this plateau, cerebral blood flow will decrease and above this plateau, cerebral blood flow will increase. This has lead to the development of a series of 'magic' numbers above which preterm mean blood pressure (MBP) must be maintained by any means possible. The study by Miall-Allen et al.
1 produced the first of these numbers, a MBP of 30 mm Hg. Subsequently, in recognition of different normal BPs at different gestations, a MBP above the gestation in weeks was suggested. This belief in the direct proportionality between BP and blood flow, particularly cerebral blood flow, meant that study of the effects of circulatory support measures has focused purely on whether the intervention increased the MBP above these 'magic numbers.' Anything that achieved this goal was good and anything that did not was not good. None of these studies tried to address the question of whether these interventions made any difference to anything other than the baby's BP. To the best of my knowledge, there is only one study in the history of circulatory support clinical trials that has followed the babies through to the assessment of neurodevelopmental outcomes. 4 However, when one asks people, as I did at this conference, why they support preterm circulation, it is the belief that they improve neurodevelopmental outcomes. They may do but we do not know that and we should.
Cases
Let me describe two case histories with echocardiographic measurements that are typical of those that caused us to question these established truths.
Case 1: An 8-h-old baby born at 26 weeks. The baby was ventilated with improving settings having been administered surfactant early after birth. The MBP had been within the range of 30 to 35 mm Hg. Figure 1a shows the Doppler velocities in the main pulmonary artery (MPA). Contrasting this with a baby with normal velocities, as in Figure 1b , it can be observed that these are very low. Flow in the MPA is right ventricular output (RVO), and this can be calculated from the product of cross-sectional area and mean velocity. Despite normal BP, this baby had a RVO of 92 mls kg À1 min À1 , well below the normal range of 150 to 300 mls kg À1 min À1 . The RVO is a better measure of SBF than the left ventricular output (LVO), for reasons that will be discussed later in this paper.
Case 2: A 7-day-old baby born at 27 weeks with septic shock from what turned out to be Pseudomonas aeruginosa septicemia. This baby looked terrible and had a MBP between 18 and 20 mm Hg, despite high-dose multiple inotropes and multiple volume expansions. Figure 2a shows the Doppler velocities in the ascending aorta; these are very high and represent an LVO of B600 mls kg À1 min À1 , about twice the upper limit of the normal range. Conventional thinking with regard to BP would consider this baby would have very low cerebral blood flow, yet the velocities in the middle cerebral artery were very high (Figure 2b ). This baby was in a state of vasodilatory shock with hyperdynamic circulation.
Therefore, these cases immediately raise questions about BP as a gold standard of hemodynamic health, and point to the extraordinary complexity of the preterm transitional circulation that I will now attempt to unravel for you. Pathophysiology of the preterm circulation Studies of the preterm transition circulation can be divided into those that study measures of systemic circulation and those that measure specific organ blood flow, usually for the brain with near infrared spectroscopy. The findings from the two approaches to study are not completely consistent with each other, but I will focus on the measures of SBF in this paper.
Studies of the systemic circulation
We used a measure of cardiac input, superior vena cava (SVC) flow, for studying systemic circulation, because the more usual measures of SBF, the ventricular outputs, are confounded by the ductal (confounds LVO) and atrial shunts (confounds RVO) that occur in the transitional period. 5 RVO is a much better measure than LVO, because the atrial shunts are much smaller than the ductal shunts in the early postnatal period. 6 In serial studies of SVC flow in a large cohort of preterm babies born before 30 weeks, we showed that there was a natural dip in SVC flow within the first 6 to 12 h after birth, followed by a period of recovery. 7 In some babies, SVC flow dropped to extremely low levels during this nadir, and these babies were particularly at a high risk of a range of adverse outcomes including, intraventricular hemorrhage (which seems to occur as SBF improves), death, necrotizing enterocolitis and a poor 3-year neurodevelopmental outcome. 4, [7] [8] [9] Data are now emerging from other groups that are duplicating some of these findings. 10 Most importantly, there is a very weak relationship between these measures of SBF and BP (Figure 3) . 7, 11 This finding has now been duplicated in several studies in the literature; indeed Groves et al., 12 found an inverse relationship between SVC flow and MBP. The strongest associations with low SVC flow are lower gestation and, at the time of the measurement, higher mean airway pressure, larger ductal diameter and high vascular resistance ( Figure 4 ). 7 Our hypothetical model for what is going wrong here is based on the recognition that these babies are essentially exteriorized fetuses whose physiology is adapted to an intrauterine environment. For the heart, this means a low-resistance placentaldominated circulation. The extrauterine environment is characterized by higher resistance, particularly in the systemic circulation, and we speculate that the immature myocardium may struggle to adapt to this. When this is compounded by the negative circulatory effects of positive intrathoracic pressure and by large shunts of blood out of the systemic circulation, then critically low SBF can occur as a result.
Systemic blood flow after the first 24 h Low SBF seems to be a problem mainly during the first 24 h. After this time, as seen in the second of the two cases presented above, the problem is more of low BP with normal or high SBF. This hemodynamic indicates a loss of vascular resistance or vasodilatory shock. Figure 5 shows data on serial RVO from an ongoing study of hemodynamics in septic shock (shown with permission from Dr Koert De Waal); it can be seen that all the babies have RVO within or above the normal range.
Treatment
Focusing on the early transitional period and very preterm babies, and making empirical derivations from the pathophysiology described above, possible approaches include minimizing ventilatory pressures, early closure of large ducts and reducing afterload.
Minimizing ventilatory pressures
Common sense dictates that one should try and use the lowest ventilator pressures possible, not just to reduce the risk of lung injury but also to avoid hypocarbia; the latter being a potent method for reducing cerebral blood flow. One aspect of ventilator pressure manipulation that can vary is the use of positive end expiratory pressure. We studied the hemodynamic effect of a short-term increase in positive end expiratory pressure (PEEP) from 5 to 8 cm H 2 O and then back again. 13 The results are summarized in Figure 6 . Although the overall effect was null, there were babies with both significant increases and decreases in the flow, highlighting the way summary statistics can mask important individual effects. We could not find clear predictors of change in SBF in response to a change in PEEP, although babies who showed improvement in lung compliance with higher PEEP were more likely to improve SBF.
Reducing afterload
Dopamine is probably the most common first-line inotrope, because it improves BP more consistently than other inotropes, such as dobutamine.
14 However, much of dopamine's effect on BP is achieved through its a vasoconstrictor effects, and this may not be a positive effect in a baby with afterload compromise. We randomized babies with low SVC flow to dopamine or dobutamine, hypothesizing that the latter would improve the flow more because of its afterloadreducing effects.
15 Figure 7 , summarizes the results at the highest dose, in which dobutamine produced significantly better improvements in SBF despite having a significantly less effect on BP. However, note the range of individual responses in both groups and one of the most striking findings of this study was the number of babies in both groups who failed to improve or maintain improvement in response to either of the inotropes.
Owing to this therapeutic failure rate, we decided to investigate the potential for a preventative approach to this problem. We were struck by the similarities between what we were seeing in these very preterm babies and the low-cardiac-output-syndrome seen after cardiac surgery. Milrinone, a phosphodiaesterase-5 inhibitor, has been successfully preventatively used after cardiac surgery because of its inotropic and vasodilatory properties. 16 In open label, dose escalation and pharmacokinetic studies, we established an appropriate milrinone regimen for very preterm babies.
17, 18 We then tested this regimen in a randomized placebo-controlled trial with a view to preventing low SBF during the transitional period. 19 High-risk babies (mainly born before 28 weeks) were randomized to milrinone infusion (loading with 75 mg kg À1 h À1 for 3 h, maintained at 20 mg kg À1 h À1 until 18 h of age) or a placebo. The results were disappointing and we could show no effect of milrinone on the measures of SBF flow (RVO or SVC flow) during the first 24 h. The reasons for this lack of effect are unknown, although we did show that milrinone seemed to slow the constriction of the ductus and this may have counterbalanced any potential positive effects on systemic circulation. At this stage, milrinone cannot be recommended for this purpose in preterm babies.
Early closure of large ducts
The early constrictive behavior of the ductus arteriosus predicts a range of adverse outcomes, including intraventricular hemorrhage and pulmonary hemorrhage, but most importantly it predicts the outcomes for those babies in whom the ductus is going to remain open (Figure 8) . Thus, the concept using early postnatal echocardiography for selecting poorly constricting ducts for medical closure is an appealing one. In an early study that we performed in this area, the hemodynamic outcome measures were probably too short term to prove or disprove the hemodynamic benefits of this strategy. 20 Thus, currently, we are starting a trial of early (<12 h) echocardiographically targeted closure of the ductus.
Where to now with the study of circulatory support? There is a real lack of good evidence in this fieldFwe know what is good for improving BP and, to a lesser extent, blood flow, but we do not know whether any of this benefits the babies. Specifically, there is a lack of any evidence regarding the effects of circulatory support on improving neurodevelopmental outcomes. Indeed, to the best of my knowledge, only one trial, the dopaminedobutamine study described above, has looked at this. 4 . There was no difference in neurodevelopmental outcomes. There is an Evidence vs Experience conflict here. The world of large clinical trials demands easily applied therapies that can be delivered to large number of babies with minimal diagnostic steps before enrollment. Thus, the search is always for a one-size-fits-all treatment, such as surfactant or antenatal steroids. To carry this out, we must assume a degree of mechanistic homogeneity, which in the field of hemodynamics just does not reflect the reality. Figure 9 shows a schema of all the factors that may contribute to hemodynamic compromise, including immaturity of the myocardium, positive pressure ventilation, shunting out of the systemic circulation, afterload compromise in the systemic and pulmonary circulation, uncertain volume status and vasodilatation. Any or all of these factors could contribute at any one time, and the question in my mind is whether the progress in this field will be made with large randomized trials or with the search for better diagnostic modalities to help us unravel this complexity in an individual baby.
Future large randomized trials
The holy grail of medical evidence is to show a treatment that reduces mortality and/or morbidity. The primary problem here is that despite a lack of evidence of benefit, it is probable that most neonatologists' level of equipoise would not let them use a placebo in a baby with clinical evidence of circulatory problems. How might we design such a study for the inotropes that we use? We could take a group of babies with low BP and randomize them into two different inotropes ( Figure 10, design 1) . The problem here would be that there would be an inevitable contamination of the group receiving the inotrope that was less effective in improving BP. Another approach would be to say that all inotropes are much of a muchness and randomize the babies to BP thresholds, say for example, 30 vs 24 mm Hg. The trial could allow the use of anything that keeps BP above that threshold ( Figure 10, design 2) . Blinding might be achieved in a way similar to that used in the oxygen-targeting trials, in which the monitors are adjusted to read above or below the actual measure to achieve the two difference groups. This design would probably produce more clinically useful results. The final approach would be to apply the preventive design that we used for milrinone but using other inotropes (Figure 10,  design 3 ). This has the advantage that one can use a placebo and, Figure 8 The range of constriction of the ductus arteriosus at 5 h of age in a cohort of babies born before 30 weeks. The triangles show the babies who later required treatment for a clinically apparent patent ductus arteriosus (PDA). The color reproduction of this figure is available on the html full text version of the paper. empirically in preterm neonatology, it is better to prevent a pathology than to treat it once it has occurred.
Future better hemodynamic diagnosis
There is a wealth of information that can be obtained from functional echocardiography. To achieve its potential, there is a need to move it to the point of care where it is performed by the attending neonatologist and not by consulting specialists, who have to come in from off-site or other departments. There are clearly a range of political, financial and skill-acquisition hurdles that have to be crossed before this can happen, and the progress in this differs markedly in different health-care settings. 21 Even then echocardiography is limited by the fact that it is still an intermittent sampling measure. Continuous esophageal Doppler devices that record descending aortic velocities are available in the world of adult critical care and might offer intriguing possibilities if they could be miniaturized sufficiently for the preterm neonate. Alternatively, the pulmonary artery (PA) might lend itself to an external Doppler device for continuous measurement, but again, miniaturization and fixation would be a challenging task. The near infrared spectroscopy monitors offer the potential for continuous monitoring, but more work is needed in this area for validating their use in the clinical arena. Ultrasound and near infrared spectroscopy will measure oxygen delivery and levels but not its utilization; again in the adult world of critical care, mixed venous saturation is often used as a measure of oxygen utilization and methods for measuring this in the neonate could be explored. Once more the challenge will be the size and the complexities of the transitional circulation. Right atrial blood will often be contaminated by oxygenated blood shunting from the left atrium. A final comment I would make on physiological measures would be that we tend to spend more time worrying about whether a measure correlates with another (gold standard) measure, than we do worrying about whether the measure matters to the baby. In other words, clinical validation is just as important as physiological validation. The dearth of data on the relationship between cerebral near infrared spectroscopy measures and neurodevelopmental outcomes is a good example of this.
In the meantime, what should we do? Common sense dictates that circulatory compromise is not good for babies; thus, I suspect most would agree that we should do something if we are concerned about the circulation. The approach I suggest here is empirical, based on our observations, and I do not know whether this is the best approach to improve outcomes for the babies.
My (probably rather simplistic) model of circulation is shown in Figure 11 . I see the circulation as a set of scales, which are balancing vasoconstriction on the one arm and vasodilation on the other. In the middle is the immature heart of the very preterm baby. Tipping the scales too far either way is probably not good. Over-constricting the circulation may result in low blood flow despite normal BP, whereas over-dilating will cause BP to drop too far despite maintenance of blood flow. An immediate problem is apparentythe correct approach for constriction is the wrong approach for dilation and vice versa. To understand where one is, one needs to know about both BP and blood flow. If only measures of pressure are available, then one needs to guess on the basis of whatever threshold for BP one wishes to apply and postnatal age. Within the first 24 h when low blood flow is most common, I would suggest up to 20 mg kg À1 min À1 of dobutamine as first line, followed by low-dose dopamine (as described below), if a minimally acceptable BP is not achieved. After 24 h, vasodilatation is much more likely, so starting with dopamine at a low dose of 4 to 6 mg kg À1 min À1 and titrating to keep BP just above the threshold level is suggested. More BP may not necessarily be better for the baby, particularly if therapeutically driven. The above doseminimization approach should reduce the risk of afterload compromise. As volume status is impossible to assess clinically unless there is extreme hypovolemia, I would use 10 mls kg À1 of whichever volume expander you like to use (we use normal saline) whenever using an inotrope. However, I would caution against continuing to push the volume expanders beyond this unless one sees a clear improvement in the response to the first bolus.
Presently to know SBF, one needs point-of-care echocardiography. In the clinical arena, I would recommend RVO measures over SVC flow, as the latter is technically more difficult. Flow is the product of cross-sectional area and mean velocity and because variations in RVO are mainly reflected in velocity, calculating pulsed Doppler maximum velocity (V max ) in the MPA is a good screening measure for low RVO. Figure 12 shows a box and whisker plot of RVO against V max in the PA. As can be seen, when the V max is above 0.45 m s À1 , the RVO is usually normal, when the V max is below 0.35 m s À1 , the RVO is usually low, between 0.35 and 0.45 m s À1 , the RVO varies and one will need to carry out the full measure. That this reflects systemic blood flow is based on an assumption that there is minimal left-to-right shunt across the foramen ovale. This is a reasonably safe assumption during the first 24 to 48 h but becomes less safe after this time.
Applying this to therapy, if this V max is low, I would use volume and dobutamine in the manner described above, whatever the BP. If the V max and the BP are normal, then I would leave them well alone. If V max is normal or high and the BP is too low, I would use volume and low-dose dopamine in the manner described above. What constitutes a BP that is too low is forever arguable, but one of the advantages of having blood flow measures is that it gives one the confidence to not treat borderline BPs if everything else looks fine. Thus, we will often leave MBPs in the mid-to-high 20s, but we would usually treat if the MBP is below 24 mm Hg. In the design of the milrinone trial, 19 we set a floor to MBP of 24 mm Hg for babies of 23 to 25 weeks and 26 mm Hg for babies of 26 to 29 weeks.
Conclusions
Hemodynamics remain an area of neonatology that is more marked by what we do not know than what we do. It is clear that it is much more complex than just measuring BP. Early postnatal preterm hemodynamic pathophysiology is characterized by low SBF, possibly relating to a mix of afterload compromise, ductal shunting and the circulatory effects of ventilation. After B24 h of age, vasodilatation seems to be the dominant pathology. In the face of this complexity, a one-size-fits-all approach to treatment that will be applicable in a large clinical trial may prove elusive. The possibility of using a measure of both pressure and flow to target an appropriate treatment needs to be explored. Disclosure N Evans has declared no conflict of interest. This paper was based on a talk presented at the Evidence vs Experience in Neonatal Practices Fifth Annual CME Conference that was supported by an unrestricted educational grant from Dey, LP. 
